Q-omics provides the consensus-scored DPM3 profile across patient tissues and cancer cell-line models. DPM3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DPM3 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, DPM3 RNA expression shows 18,488 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KICH, and THYM as cancer lineages where DPM3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPM3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPM3 survival associations across molecular data types. DPM3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPM3 RNA expression–survival associations across cancer types. High DPM3 expression shows unfavorable associations in ACC, LGG, KIRC and UCS, but favorable associations in OV and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DPM3 RNA expression.
This table summarizes DPM3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DPM3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPM3 shows lower tumor expression in KICH and higher tumor expression in LIHC, BRCA, BLCA, COAD and CHOL. The KICH box plot shows higher DPM3 RNA expression in normal versus tumor tissue (log2 FC = −1.961, t-test p < 0.001).
This table shows molecular features associated with DPM3 in patient tissues and cancer cell lines. In patient samples, DPM3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DPM3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
